Biopharma company Jazz Pharmaceuticals (NASDAQ:JAZZ) will be reporting results tomorrow after market close. Here’s what to expect.
Data protection and security software company Varonis (NASDAQ:VRNS) will be reporting earnings tomorrow after market hours. Here’s what to expect.
Wellness products company Nature’s Sunshine (NASDAQ:NATR) will be announcing earnings results tomorrow after market hours. Here’s what you need to know.
Online fashion retailer Revolve (NASDAQ:RVLV) will be reporting results tomorrow afternoon. Here’s what to expect.
Global hospitality company Marriott (NASDAQ:MAR) will be reporting results tomorrow before the bell. Here’s what you need to know.
Residential swimming pool manufacturer Latham (NASDAQ:SWIM) will be reporting earnings tomorrow afternoon. Here’s what to look for.
The de minimis exemption ended on Friday, impacting small US businesses that rely on imports. JPMorgan Asset Management global market strategist Jordan Jackson and EY chief economist Gregory Daco discuss the pressures these businesses face and the potential economic consequences. To watch more expert insights and analysis on the latest market action, check out more Market Domination here.
Does the old adage "sell in May and go away" still hold true in this market environment? Yahoo Finance markets and data editor Jared Blikre — who also hosts the Stocks In Translation podcast — gives a history lesson on how this trading practice performed for stock traders (^DJI, ^IXIC, ^GSPC) over the past 100 years, weighing in on whether its a winning strategy in regards to market seasonality. Twice a week, Stocks In Translation cuts through the market mayhem, noisy numbers and hyperbole to give you the information you need to make the right trade for your portfolio. You can find more episodes here, or watch on your favorite streaming service. To watch more expert insights and analysis on the latest market action, check out more Catalysts here.
Pipeline: Delivered on our commitment to a more focused R&D strategy by advancing a streamlined portfolio of 5+ clinical and preclinical programs in oncology and rare disease, while deprioritizing 3 clinical programs and 1 preclinical program following a strategic, data-driven reviewPartnerships: Achieved fourth milestone in Sanofi collaboration, generating $7 million for an orally active small-molecule lead with best-in-class potential in autoimmune diseasesPlatform and Operations: Implemented
The longtime CEO of Berkshire Hathaway announced he is handing the reins to Greg Abel at the end of this year, putting the finishing touches on a succession plan that has been in place since 2021.